Enliven Therapeutics, Inc.
ELVN
$36.38
$0.270.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.97% | 111.28% | 18.26% | 22.78% | 12.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.21% | 27.47% | -7.29% | 16.18% | 21.96% |
| Operating Income | 12.21% | -27.47% | 7.29% | -16.18% | -21.96% |
| Income Before Tax | 17.23% | -27.99% | 12.99% | -28.49% | -25.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.23% | -27.99% | 12.99% | -26.99% | -25.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.23% | -27.99% | 12.99% | -26.99% | -25.53% |
| EBIT | 12.21% | -27.47% | 7.29% | -16.18% | -21.96% |
| EBITDA | 12.05% | -27.68% | 7.24% | -16.22% | -22.04% |
| EPS Basic | 34.03% | -2.58% | 32.35% | -17.16% | -5.45% |
| Normalized Basic EPS | 34.03% | -2.55% | 32.58% | -13.95% | -5.44% |
| EPS Diluted | 34.03% | -2.58% | 32.35% | -17.16% | -5.45% |
| Normalized Diluted EPS | 34.03% | -2.55% | 32.58% | -13.95% | -5.44% |
| Average Basic Shares Outstanding | 25.47% | 24.78% | 28.65% | 8.38% | 19.04% |
| Average Diluted Shares Outstanding | 25.47% | 24.78% | 28.65% | 8.38% | 19.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |